Research Press Releases

05.31.2024

Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression

03.12.2024

Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)

11.02.2023

Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting

06.26.2023

Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus

06.01.2023

Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options

12.29.2022

Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate

12.01.2022

Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day

12.01.2022

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate 

10.04.2022

Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial

09.19.2022

Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union

09.14.2022

Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine

08.08.2022

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15